Key Highlights

  • SLXN rose 14.82% on 29 May 2026 to $4.91 on the first day of split-adjusted trading following a 1-for-10 Reverse Stock Split effective after 28 May close.
  • Relative Volume of 0.09x is light but mechanically expected post-split; share count reduced 10x, so same dollar volume translates to one-tenth the share count.
  • SIL204 (RNA-interference pancreatic cancer therapy) received Israeli Ministry of Health and Helsinki Ethics Committee approval to advance to Phase 2/3 trial, providing clinical narrative support for the repricing.

About Silexion Therapeutics Corp.

Silexion Therapeutics Corp. (Nasdaq:SLXN) is a clinical-stage biotechnology company focused on RNA-interference therapies for cancer. SIL204 is the lead candidate targeting locally advanced pancreatic cancer, with development partnerships at Tel Aviv Sourasky Medical Center in Israel. The $2.06M micro-cap biotech employs reverse splits to maintain Nasdaq listing compliance.

Silexion Therapeutics Corp. closed Friday, 29 May 2026 at $4.91, up 14.82% on volume of approximately 313.47 thousand shares with relative volume of 0.09x. Market cap closed near $2.06 million, placing SLXN in micro-cap biotech territory with trailing twelve-month EPS of $94.56.

Reverse Split Mechanics and Nasdaq Compliance

Silexion announced and executed a 1-for-10 ordinary share reverse split, effective after market close on 28 May 2026, with split-adjusted trading beginning at the open on 29 May under the existing SLXN ticker. Every ten ordinary shares issued and outstanding were automatically combined into one share; Par Value increased from $0.0135 to $0.135 per share. The reverse split was intended to help Silexion maintain compliance with Nasdaq's minimum bid price requirement—a recurring challenge for clinical-stage microcaps navigating development cycles without near-term Revenue. The mechanically adjusted stock price increased approximately 10-fold from pre-split levels (pre-split equivalent ~$0.49 → post-split $4.91), providing immediate price relief from penny-stock status. The light relative volume of 0.09x is normal and expected for a post-split first day: with share count now one-tenth of pre-split levels, dollar volume that was typical pre-split now maps to roughly one-tenth the share count post-split.

Clinical Narrative: Phase 2/3 Trial Approval Provides Fundamental Support

Parallel to the reverse split execution, Silexion reported meaningful clinical progress on SIL204. The company received approval from the Israeli Ministry of Health and the Helsinki Ethics Committee at Tel Aviv Sourasky Medical Center to advance SIL204 toward a Phase 2/3 clinical trial in locally advanced pancreatic cancer. Preclinical data has been reported, and clinical Manufacturing has commenced. The combination of clinical approval and reverse-split repricing creates a coherent narrative: Silexion is addressing a Nasdaq compliance constraint while simultaneously advancing its lead asset toward late-stage development. This two-part story likely explains the 14.82% move, which is modest on top of the mechanical 10x price adjustment. The clinical catalyst, while not a blockbuster trial result, provides the kind of substantive narrative that can sustain biotech investor interest beyond pure technical repricing.

Capital-structure/">Capital Structure and Dilution Path

With a $2.06M market cap and a clinical-stage program requiring funding through Phase 2/3 trials, Silexion faces material capital requirements ahead. Dilution from future Equity raises is highly likely and will be a key determinant of Shareholder value. The reverse split addresses the Nasdaq minimum bid price floor, but additional capital actions—equity raises, Warrant exercises, or subsequent reverse splits—remain probable. Investors should monitor SEC filings, particularly 8-Ks and 6-Ks, for capital structure announcements and clinical progress updates.

What Matters Next

Watch for Silexion announcements regarding Phase 2/3 trial start date and enrolment progress, additional preclinical or clinical data readouts for SIL204, strategic partnerships or licensing agreements, capital raises and dilution activity, and Nasdaq listing status updates. clinicaltrials.gov registry and Silexion's Investor relations feed are primary references for trial and funding updates. The durability of the post-split rally will depend on tangible clinical progress and capital structure management.